You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
PMLEYear 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023US marketPopulation (m) 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0 290.0% PMLE patients 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00No. PMLE patients (m) 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00 29.00% Severe PMLE patients 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5No. severe PMLE patients (m) 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45% Maximum penetration of Melanotan 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0Total patients treated at peak (m) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15% of peak penetration 0.0 0.0 0.0 2.0 20.0 40.0 60.0 80.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 90.0 70.0 30.0 10.0Cost of treatment per patient per year ($) 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0Revenue generated ($m) 0.0 0.0 0.0 1.5 14.5 29.0 43.5 58.0 72.5 72.5 72.5 72.5 72.5 72.5 72.5 65.3 50.8 21.8 7.3EU market (top 5 countries)Population (m) 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0% PMLE patients 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00No. PMLE patients (m) 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00% Severe PMLE patients 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5No. severe PMLE patients (m) 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50% Maximum penetration of Melanotan 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0Total patients treated at peak (m) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15% of peak penetration 0.0 0.0 0.0 2.0 20.0 40.0 60.0 80.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 90.0 70.0 30.0 10.0Cost of treatment per patient per year ($) 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0Revenue generated ($m) 0.0 0.0 0.0 1.5 15.0 30.0 45.0 60.0 75.0 75.0 75.0 75.0 75.0 75.0 75.0 67.5 52.5 22.5 7.5Australia/New ZealandPopulation (m) 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0 24.0% PMLE patients 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00No. PMLE patients (m) 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40% Severe PMLE patients 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5No. severe PMLE patients (m) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12% Maximum penetration of Melanotan 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0Total patients treated at peak (m) 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01% of peak penetration 0.0 0.0 0.0 2.0 20.0 40.0 60.0 80.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 90.0 70.0 30.0 10.0Cost of treatment per patient per year ($) 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0 500.0Revenue generated ($m) 0.0 0.0 0.0 0.1 1.2 2.4 3.6 4.8 6.0 6.0 6.0 6.0 6.0 6.0 6.0 5.4 4.2 1.8 0.6US $m 0.0 0.0 0.0 1.5 14.5 29.0 43.5 58.0 72.5 72.5 72.5 72.5 72.5 72.5 72.5 65.3 50.8 21.8 7.3EU $m 0.0 0.0 0.0 1.5 15.0 30.0 45.0 60.0 75.0 75.0 75.0 75.0 75.0 75.0 75.0 67.5 52.5 22.5 7.5Aus/NZ $m 0.0 0.0 0.0 0.1 1.2 2.4 3.6 4.8 6.0 6.0 6.0 6.0 6.0 6.0 6.0 5.4 4.2 1.8 0.6Total $m 0.0 0.0 0.0 3.1 30.7 61.4 92.1 122.8 153.5 153.5 153.5 153.5 153.5 153.5 153.5 138.2 107.5 46.1 15.4<strong>EPITAN</strong>Source: T&G research19
Change language